Horizon Continues to Build Rare Disease Pipeline with US$3.05 B Viela Buy
By Michelle Liu
Pharma Deals Review: Vol 2021 Issue 2 (Table of Contents)
Published: 4 Feb-2021
DOI: 10.3833/pdr.v2021.i2.2588 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
In its latest acquisition to strengthen its orphan drug portfolio, Horizon Therapeutics has agreed to acquire Viela Bio, a clinical-stage biotechnology company focused on the development and commercialisation of therapeutics for autoimmune and severe inflammatory diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS